Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1998-05-29
2002-06-11
Celsa, Bennett (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06403605
ABSTRACT:
TECHNICAL FIELD
The present application relates to pharmaceutical formulations and to medical methods of treatment. More particularly, the present invention concerns the use of a compound which acts as a central nervous system sexual response initiator for the normalization of the timing of sexual response in humans and for the prophylaxis or treatment of long-term damage to genital organ.
BACKGROUND OF THE INVENTION
Proper sexual functioning in men and women depends upon a combination of steps including 1) establishment of the appropriate anticipatory mental set (“desire”), 2) effective vasocongestive arousal (an erection in the male sufficient for vaginal penetration and, in the female, clitoral erection, vaginal engorgement and lubrication), and 3) orgasm. The timing of these steps between partners engaging in sexual relations is mediated by one or more of several compounds which act in neurological pathways in the mesencephalon or mid-brain. These pathways include those termed the serotonergic, dopaminergic, oxytocinergic, and nitroxidergic mid-brain pathways. Timing of the various aspects or parameters of sexual response between partners engaging in sex is important and often mis-matched due to psychological, or sometimes biogenic, dysfunction in one or both of the partners. Even in sex partners having sexual responses deemed to fall within the norm, there is a frequent mis-match of the timing of response.
Orgasm in the male includes the sensation of emission followed by ejaculation. The sensation of emission is one of ejaculatory inevitability and is mediated by contractions of the prostate, seminal vesicles, and urethra. Orgasm in the female is accompanied by contractions of the muscles that line the wall of the outer third of the vagina. In both sexes, generalized muscular tension, perineal contractions and involuntary pelvic thrusting usually occur. Orgasm is followed by resolution, a sense of general relaxation, well-being, and muscular relaxation. During this phase men are physiologically refractory to further erection and orgasm for a variable period of time. In contrast, women may be able to respond to additional stimulation almost immediately.
Sexual response is mediated by a balanced interplay between the sympathetic and parasympathetic nervous systems. Vasocongestion, or erectile tumescence, is largely mediated by parasympathetic (cholinergic) outflow, whereas orgasm is predominantly sympathetic (adrenergic). Ejaculation is almost entirely sympathetic, whereas emission involves a much more finely balanced combination of sympathetic and parasympathetic stimulation.
Normal biological response in humans results in ejaculation typically within about two minutes or more following vaginal penetration. Most women are unable to reach orgasm within this short period of time, one cause of the problem of inappropriate timing of sexual response between sexual partners, even when the sexual responses of both are within physiological norms. In the case of the sexual dysfunction in males known as premature ejaculation, the problem is further exacerbated.
Premature ejaculation in males may have either a psychogenic or biogenic origin in a particular individual, and various treatment methods have been suggested. These include counseling and techniques for learning control of ejaculation and the use of serotonin re-uptake inhibitors such as fluoxetine hydrochloride (Prozac®) and sertraline hydrochloride (Zoloft®) to delay the onset of the sensation of emission.
The problem of inappropriate timing of sexual response is not limited to the human species, but occurs also in lower mammals as well, for example, in the breeding of valuable commercial animals such as horses, cattle, sheep, swine and the like and domesticated pets such as dogs and cats.
U.S. Pat. No. 5,770,606 (Ser. No. 08/546,498) discloses a method of ameliorating erectile dysfunction in a male patient by administration of apomorphine or a salt thereof in an amount sufficient to induce an erection adequate for vaginal penetration, but less than that which induces nausea.
The need remains, however, for the development of effective means to normalize the timing of sexual response in mammals, including humans and, in particular, in those cases involving premature ejaculation in human males.
In addition, there is a need for agents for the prophylaxis and treatment of long-term degradative effects or damage to genital organ tissues in mammals.
REFERENCES:
patent: 2818855 (1958-01-01), Miller
patent: 4127118 (1978-11-01), Latorre
patent: 4521421 (1985-06-01), Foreman
patent: 4543256 (1985-09-01), Neumeyer
patent: 4687773 (1987-08-01), Neumeyer et al.
patent: 4727064 (1988-02-01), Pitha
patent: 4801587 (1989-01-01), Voss et al.
patent: 5242391 (1993-09-01), Place et al.
patent: 5270323 (1993-12-01), Milne, Jr. et al.
patent: 0 579 435 (1994-01-01), None
patent: 0 714 663 (1996-06-01), None
patent: WO 87/04621 (1987-08-01), None
patent: 94/22445 (1994-10-01), None
patent: WO 95/28930 (1995-11-01), None
patent: WO 97/137710 (1997-04-01), None
Harrison's Principles of Internal Medicine, Ninth Edition,: “Section 8: Alterations in Reproductive and Sexual Function—Sub-Section 47: Disturbances of Sexual Function and Reproduction in Men”, eds.: Isselbacher et al., New York: McGraw-Hill Book Compa.*
Segraves, “Effects of Psychotrophic Drugs on Human Erection and Ejaculation,” Arch. Gen. Psychiatry, vol. 46, <arch 1989, pp. 275-284.*
Samarthji Lal, et al., Apomorphine-Induced Penile Tumescence in Impotent Patients-Preliminary Findings, 1987Prog. Neuro-Pshychoparmacol&Biol. Psychiat., vol., II, pp. 235-242.
Jeremy P. W. Heaton, M.D., et al., Recovery of Erectile Function by the Oral Administration of Apomorphine, Feb. 1995,Urology, vol. 45, No. 2, pp. 200-206.
I. Goldstein and JR Berman, Vasculogenic Female Sexual Dysfuction: Vaginal Engorgement and Clitoral Erectile Insufficiency Syndromes,International Journal of Impotence Research(1998) 10, Suppl 2, pp. S84-S90.
R.T. Segraves, Editorial: Pharmacological Era in the Treatment of Sexual Disorders, (1998)Journal of Sex&Marital Therapy, vol. 24, pp. 67-68.
Tagliamonte et al., Pharm. Biochem. and Behavior vol. 2, pp. 257-260 (1974).
Laduron et al., Biochem. Pharmacology, vol. 28, pp. 2161-2165 (1979).
Baldessarini et al., in Gessa et al., eds., Apomorphine & Other Dopaminomimetics, vol. 1, Basic Pharmacology, pp. 219-288 (1981).
Lal et al., J. Neural Transmission, vol. 54, pp. 75-84 (1982).
Reynolds, James E. F., ed., Martindale, 28th Edition, pp. 891-892 (1982).
Gower et al., European J. of Pharmacology, vol. 122, pp. 239-244 (1986).
Melis et al., Brain Research, vol. 415, 98-104 (1987).
Segraves et al., Archives of Sexual Behavior, vol. 16, No. 2, pp. 125-137 (1987).
Danjou et al., Br.J. Clin. Pharmac., vol. 26, pp. 733-739 (1988).
Lal S., Prog. Neuro-Psychopharm. & Biol. Psych., vol. 12, pp. 117-164 (1988).
Pehek et al., Pharm. Biochem. and Behavior 31:201-208 (1988).
Danjou et al., J. Pharamacol. Methods, vol. 21, pp. 61-69 (1989).
Gancher et al., AM. Neurol., vol. 26, pp. 232-238 (1989).
Segraves R. T., Arch. Gen. Psych., vol. 46, pp. 275-284 (1989).
Durif et al., Eur. J. Clin. Pharmacology, vol. 41, pp. 493-494 (1991).
Essink et al., J. Chromatography, vol., 570, pp. 419-424 (1991).
Gancher et al., Movement Disorders, vol. 6, No. 3, pp. 212-216 (1991).
Heaton et al., J. Urology, vol. 145, pp. 192-194 (1991).
Heaton et al., J. Urology, vol. 145, pp. 1099-1102 (1991).
Lal et al., J. Psych. Neurosci., vol. 16, No. 5, pp. 262-266 (1991).
Montastruc et al., Clin. Neuropharmacology, vol. 14, No. 5, pp. 432-437 (1991).
Panegyres et al., Med. J. Australia, vol. 155, pp. 371-374 (1991).
Segraves et al., J. Urology, vol. 145, pp. 1174-1175 (1991).
Durif et al., Clinical Neuropharmacology, vol. 16, No. 2, pp. 157-166 (1993).
Heaton et al., J. Urology, vol. 151, pp. 797-800 (1994).
Bancroft, J., editor, The Pharmacology of Sexual Function and Dysfunction, pp. 225-229 (1995).
Goodman and Gilman, eds., The Pharmacological Basis of Therapeutics, 9th Edition, pp. 4-9 (1996).
Adams Michael A.
Heaton Jeremy P. W.
Celsa Bennett
Friend Tomas
Janssen Jerry F.
Miernicki Steeg Carol
Queen's University at Kingston
LandOfFree
Methods for the normalization of sexual response and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the normalization of sexual response and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the normalization of sexual response and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2937625